Autopsy report · NCT07066254
The Mepilex Cesarean Delivery Trial
Cause of deathFutility, also regulatory or ethics
“Proposed superiority study framework was not approved by the IRB. Study will be redeveloped as a non-inferiority study and resubmitted to the IRB.”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Na
- Sponsor
- Montefiore Medical Center
- Sponsor type
- University, hospital or other
- Conditions
- Surgical Site Infection Following Cesarean Delivery
- Interventions
- Mepilex Ag Dressing; Standard Surgical Dressing (Telfa non-adhesive dressing, gauze, and Primapore adhesive bandage)
- Participants
- 0
Trials that died the same way
- Retroperitoneal Ligation of Uterine Artery in Total Laparoscopic Hysterectomy for Enlarged Uterus
“IRB did not approve this study.” - Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant
“did not move forward with IRB approval, competing study” - Fecal Transplantation for Primary Clostridium Difficile Infection
“Pre-specified non-inferiority criterion met at interim analysis.” - Virtual Reality and Spinal Stimulation to Improve Arm Function
“No IRB application has been prepared for this study and other studies have taken priority. The study team will not be working on this study for the foreseeable future.” - Real-time 3-Dimensional Echocardiography for Assessment of Cardiac Function and Congenital Heart Disease
“Study did not receive IRB approval.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.